Ligand Reports First Quarter 2023 Financial Results
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Ligand to Report Fourth Quarter Financial Results on February 22
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Ligand Provides Highlights from its Investor and Analyst Day Event
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Ligand to Hold Investor and Analyst Day on December 13
Ligand Reports Third Quarter 2022 Financial Results
Ligand Announces Completion of OmniAb Spin-Off
Ligand Distribution of OmniAb Complete and Business Combination Closed
Ligand to Report Third Quarter Financial Results on November 7
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
